Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Swedish Drug And Device To Go Head-To-Head In The GERD Space

Executive Summary

Two Swedish companies are working on tackling GERD – one with a drug, one with a device.

You may also be interested in...



Kidney Inflammation Warning For PPI Omeprazole In Europe

Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.

Execs On The Move: January 2024

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Chapter 11 Bankruptcy, Not A Party You Would Want An Invitae For

Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel